Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Arletta Pharma Solutions Appoints Steve van Os, MD, as Chief Medical Officer
Seasoned biotech executive brings more than two decades of global clinical development, medical affairs and regulatory leadership across oncology, women's health and endocrinology Appointment supports Arletta's next chapter as the company prepares…
Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmaker
Recent setbacks for Danish biotech Zealand Pharma forced analysts to rethink the company's obesity strategy While its drug survodutide disappointed in terms of dropout rates, analysts remain upbeat on its amylin-based drug petrelintide An emerging…
US launches Germany pharma pricing probe, raising threat of new tariffs
The United States on Thursday started an investigation into Germany over its pharmaceutical pricing policies and other practices, in a move that could lead to fresh tariffs. The probe seeks to determine if 'persistent underpayment for innovative…
US launches trade probe on Germany over pharma pricing
The probe seeks to determine if 'persistent underpayment for innovative pharmaceutical products by Germany is unreasonable or discriminatory and burdens or restricts US commerce,' said the US Trade Representative's office. The move was launched…
Alembic Pharma gets tentative nod from USFDA for generic cancer drug
Alembic Pharmaceuticals Ltd on Friday said it has received tentative approval from the US health regulator for its generic version of cancer treatment drug Binimetinib tablets. The tentative approval by the US Food & Drug Administration (USFDA) is…
U.S. opens tariff probe targeting Germany's drug pricing policies
The U.S. said the probe will examine whether 'persistent underpayment' for medicines by Germany is discriminatory. 'President Trump has made clear that American patients should not be shouldering a disproportionate share of global pharmaceutical…
River Road Asset Management LLC Decreases Stock Holdings in Royalty Pharma PLC $RPRX
River Road Asset Management LLC reduced its stake in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 3.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned…
5,670 Shares in Ascendis Pharma A/S $ASND Purchased by Seven Fleet Capital Management LP
Seven Fleet Capital Management LP bought a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 5,670…
Is TG Therapeutics, Inc. (TGTX) A Good Stock To Buy Now?
Is TGTX a good stock to buy? We came across a bullish thesis on TG Therapeutics, Inc. on TradersPro's Substack. In this article, we will summarize the bulls' thesis on TGTX. TG Therapeutics, Inc.'s share was trading at $50.54 as of June 16. TGTX's…
The vaccines and treatments being developed for Ebola outbreak
There are no vaccines or treatments for the strain of Ebola that has killed more than 200 people in the Congo and Uganda, but several are being urgently developed in the hope of reining in the outbreak. More than 875 cases of the Bundibugyo strain…
Nifty Prediction Today - June 19, 2026: Nifty futures: Recovery not ruled out despite weak opening
Nifty 50 began today's session lower at 23,991 versus Thursday's close of 24,168. The index slipped further after opening and is now at 23,950, down 0.9 per cent. The advance/decline ratio of Nifty 50 now stands at 14/36, showing a bearish bias.
Is Caris Life Sciences, Inc. (CAI) A Good Stock To Buy Now?
Is CAI a good stock to buy? We came across a bullish thesis on Caris Life Sciences, Inc. on InfoArb Sheets's Substack. In this article, we will summarize the bulls' thesis on CAI. Caris Life Sciences, Inc.'s share was trading at $18.47 as of June…
Tarsus Stock: Not Cheap, But XDEMVY Makes The Valuation Work (NASDAQ:TARS)
Tarsus Pharmaceuticals is rated a buy, driven by XDEMVY's rapid market capture and strong commercial momentum. TARS trades at 3.3–3.5x 2026 guided sales, supported by 85% YoY sales growth and ~93% gross margin guidance. The Demodex…
Americold Realty Trust: A Chilly Upside For Cold-Storage REIT That Grew Globally
Albert Anthony is the pen name of a business author on Amazon and his newest book is 'How To Pick Stocks: 8 Steps For Long-Term Investing with Fundamental & Technical Analysis,' now available as a 2026 edition paperback and Kindle ebook in several…
New Position Statement on TB Testing and IL Inhibitors in Patients With Psoriasis
A new Joint Position Statement from the National Psoriasis Foundation concludes that patients being treated with IL-17 or IL-23 inhibitors need not be tested for latent tuberculosis (TB) infection in most cases. The statement was released in March…
Receive a Daily briefing on Pharma Industry News
Get Started